J Korean Diabetes > Volume 14(3); 2013 > Article
The Journal of Korean Diabetes 2013;14(3):111-119.
DOI: https://doi.org/10.4093/jkd.2013.14.3.111    Published online September 30, 2013.
DPP-4 억제제의 비교
김남훈, 김신곤
Comparison of DPP-4 Inhibitors.
Nam Hoon Kim, Sin Gon Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr
Abstract
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them.
Key Words: Dipeptidyl-peptidase IV inhibitors, Incretins, Diabetes mellitus
TOOLS
METRICS Graph View
  • 2 Crossref
  •  0 Scopus
  • 3,091 View
  • 247 Download
Related articles


Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer